Alla Solyar, MD
Otolaryngology · St Petersburg, FLNPI 1265762108
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,900 of the $5,920 with a category attached, or 65.9%. Optinose US, Inc. accounts for 86.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $5,173 and has fallen 96.1% since, to $203 in 2025.
Across 20 payments — averaging $296.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$5K
- Regeneron Healthcare Solutions, Inc.$213
- Intersect ENT, Inc.$194
- CSL Behring$125
- Acclarent, Inc$117
- AstraZeneca$109
- plus $34 from 1 others
What the payments were for
- Speaking & faculty fees$3,90066%
- Travel & lodging$99417%
- Food & beverage$77913%
- Education$2474%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 9 | $5,128 |
| Regeneron Healthcare Solutions, Inc. | 3 | $213 |
| Intersect ENT, Inc. | 2 | $194 |
| CSL Behring | 1 | $125 |
| Acclarent, Inc | 3 | $117 |
| AstraZeneca | 1 | $109 |
| Amgen | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,920 in reported general payments places this provider in the 85th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 14 | $73,569 |
| Sodium ChlorideSodium Chloride Irrig Solution | 118 | $1,408 |
| Ipratropium Bromide | 40 | $1,204 |
| Methylprednisolone | 115 | $963 |
| Azelastine Hcl | 33 | $926 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 52 | $684 |
| Montelukast Sodium | 57 | $476 |
| Doxycycline Hyclate | 34 | $408 |
| Cefdinir | 11 | $311 |
| Fluticasone Propionate | 14 | $274 |
| Ciprofloxacin Hcl | 24 | $271 |
| Mupirocin | 23 | $266 |
| CefuroximeCefuroxime Axetil | 16 | $234 |
| Famotidine | 12 | $232 |
| Clindamycin Hcl | 16 | $189 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in St Petersburg
- Julia PfaffSt Petersburg$61K
- Shelley JaquishSt Petersburg$11K
- Cecelia DamaskOrlando$707K
- Ralph TufanoSarasota$469K
- Franklin RimellFort Myers$314K
- David BrodnerBoynton Beach$209K
- Maria SuurnaMiami$189K
- Jane DillonOrmond Beach$180K
- Jeb JusticeGainesville$142K
- Indranil DebnathWinter Park$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.